{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:53:43Z","timestamp":1775786023279,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.acuroe.2022.08.013","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T16:47:44Z","timestamp":1659804464000},"page":"521-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ"],"prefix":"10.1016","volume":"46","author":[{"given":"P.","family":"Straccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pierconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2022.08.013_bib0005","series-title":"Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours","first-page":"119","article-title":"Urothelial carcinoma in situ","author":"Sesterhenn","year":"2004"},{"key":"10.1016\/j.acuroe.2022.08.013_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5858\/arpa.2016-0411-OA","article-title":"Williamson SR CK20 and p53 immunohistochemical staining patterns in urinary bladder specimens with equivocal atypia","volume":"142","author":"Arias-Stella","year":"2018","journal-title":"Arch Pathol Lab Med."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(98)05383-5","article-title":"Expression of cytokeratin 20 redefines urothelial papillomas of the bladder","volume":"353","author":"Harnden","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0020","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2007.01.009","article-title":"FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours","volume":"52","author":"Van Oers","year":"2007","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00129039-200609000-00002","article-title":"Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium","volume":"14","author":"Yin","year":"2006","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1827.2005.01821.x","article-title":"Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia","volume":"55","author":"Kunju","year":"2005","journal-title":"Pathol Int."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0035","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.7314\/APJCP.2016.17.4.1769","article-title":"Immunohistochemical differentiation between urothelial papillomas and papillary neoplasms of low malignant potential of the urinary bladder","volume":"17","author":"Alrashidy","year":"2016","journal-title":"Asian Pac J Cancer Prev."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13000-019-0871-8","article-title":"Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?","volume":"14","author":"Alston","year":"2019","journal-title":"Diagn Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0045","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","article-title":"Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and a-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"37","author":"Aron","year":"2013","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0050","first-page":"400","article-title":"Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67","volume":"30","author":"Asgari","year":"2016","journal-title":"Med J Islam Repub Iran."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2019.151433","article-title":"Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: reclassification by international consultation on urologic disease (ICUD) recommendations","volume":"44","author":"Bang","year":"2020","journal-title":"Ann Diagn Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","article-title":"Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications","volume":"472","author":"Barth","year":"2018","journal-title":"Virchows Arch."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0065","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/PAI.0b013e3182351ed3","article-title":"Utility of cytokeratin 5\/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia","volume":"20","author":"Edgecombe","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.urolonc.2016.03.015","article-title":"Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality","volume":"34","author":"Hagiwara","year":"2016","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.anndiagpath.2013.10.006","article-title":"The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5\/6, P53, Cd138, and Her2\/Neu","volume":"18","author":"Jung","year":"2014","journal-title":"Ann Diagn Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0080","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.humpath.2010.12.024","article-title":"Flat urothelial carcinoma in situ of the bladder with glandular differentiation","volume":"42","author":"Lopez-Beltran","year":"2011","journal-title":"Hum Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13000-020-00984-2","article-title":"CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia","volume":"15","author":"Neal","year":"2020","journal-title":"Diagnostic Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.humpath.2020.02.008","article-title":"Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap","volume":"98","author":"Nguyen","year":"2020","journal-title":"Hum Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.humpath.2012.08.011","article-title":"Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases","volume":"44","author":"Oliva","year":"2013","journal-title":"Hum Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0100","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/PAS.0000000000001318","article-title":"Urothelial carcinoma in situ with plasmacytoid features. A clinicopathologic study of 23 cases","volume":"43","author":"Sangoi","year":"2019","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis:Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0120","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.MP.0000056628.38714.5D","article-title":"Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia","volume":"16","author":"Mallofr\u00e9","year":"2003","journal-title":"Mod Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/15321819.2014.899254","article-title":"Expression of topoisomerase II alpha, Ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma","volume":"35","author":"Ben Abdelkrim","year":"2014","journal-title":"J Immunoassay Immunochem."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5114\/pjp.2015.51154","article-title":"Evaluation of different p16 immunostaining methods and the prognostic role of p16\/Ki-67 combined expression in non-muscle invasive bladder cancers","volume":"66","author":"\u00d6zyalva\u00e7li","year":"2015","journal-title":"Pol J Pathol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158891","article-title":"Clinicopathological and prognostic value of Ki-67 expression in bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Tian","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0145","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s13277-013-1384-9","article-title":"Ki67 and TP53 expressions predict recurrence of non muscle invasive bladder cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.acuroe.2022.08.013_bib0150","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","article-title":"Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Amin","year":"2014","journal-title":"Am J Surg Pathol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578622000889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578622000889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:15:36Z","timestamp":1761880536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578622000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2173578622000889"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2022.08.013","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2022.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2022.02.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}